Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Mineralys Therapeutics (Nasdaq: MLYS) announced on November 26, 2025 that its Compensation Committee granted an inducement stock option covering 146,000 shares to one new non-executive employee on November 24, 2025.

The award was made under the company’s 2025 Employment Inducement Incentive Award Plan and was granted as an inducement material to the employee entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The option vests over four years: 25% on the first anniversary of the vesting commencement date (November 24, 2026) and 1/48th monthly thereafter, subject to continued service.

RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on November 24, 2025, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 146,000 shares of Mineralys common stock to one new non-executive employee.

The award was granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option will vest over a four-year period, with 25% of the total shares underlying the option vesting on the first anniversary of the award’s vesting commencement date, November 24, 2025, and 1/48th of the total shares underlying the option vesting following each one-month period thereafter, subject to continued service. The award was granted as an inducement material to the new employee entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Mineralys

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.

Contact:
Investor Relations
investorrelations@mineralystx.com

FAQ

What did Mineralys Therapeutics (MLYS) announce on November 26, 2025 about a stock option grant?

Mineralys announced a grant of an inducement stock option covering 146,000 shares to one new non-executive employee, dated November 24, 2025.

Under which plan was the Mineralys (MLYS) inducement award granted?

The award was granted under the company’s 2025 Employment Inducement Incentive Award Plan.

What is the vesting schedule for the Mineralys (MLYS) 146,000-share option awarded November 24, 2025?

The option vests over four years: 25% on the first anniversary of November 24, 2025, then 1/48th of the total shares vest each month thereafter, subject to continued service.

Why did Mineralys (MLYS) use Nasdaq Listing Rule 5635(c)(4) for this award?

The company said the award was an inducement material to the new employee entering employment and was granted in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received the inducement award from Mineralys (MLYS) on November 24, 2025?

One new non-executive employee received the inducement stock option covering 146,000 shares.

Does the Mineralys (MLYS) announcement state any immediate dilution or financial impact from the 146,000-share option?

The announcement describes the grant and vesting schedule only and does not provide figures or commentary on dilution or immediate financial impact.